Aptevo Therapeutics (APVO) Projected to Announce Quarterly Earnings on Thursday

Aptevo Therapeutics (NASDAQ:APVO) is anticipated to announce its results before the market opens on Thursday, November 5th. Analysts expect Aptevo Therapeutics to post earnings of ($3.72) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($5.31) EPS for the quarter, beating analysts’ consensus estimates of ($6.02) by $0.71. On average, analysts expect Aptevo Therapeutics to post ($17.04) EPS for the current fiscal year and ($6.59) EPS for the next fiscal year.

Aptevo Therapeutics Stock Up 1.6%

Shares of NASDAQ APVO opened at $1.30 on Thursday. The stock has a market cap of $2.35 million, a P/E ratio of -0.03 and a beta of 1.67. The firm’s 50-day simple moving average is $1.91 and its 200 day simple moving average is $4.49. Aptevo Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $28.44.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company developing targeted immunotherapies for cancer and other serious diseases. The company is headquartered in Seattle, Washington, and was established in 2016 as a spin-off from Emergent BioSolutions.

Aptevo’s research is based primarily on its ADAPTIR and ADAPTIR-FLEX antibody platforms, which are designed to create bispecific immune-cell engagers. These therapies are intended to connect immune cells with cancer cells or activate immune pathways to produce a targeted response.